CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.
CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath (taurolidine and heparin) to its facilities in the US.
專注於爲危及生命的疾病和病症開發治療產品的生物製藥公司CorMedix Inc.（納斯達克股票代碼：CRMD）今天宣佈，它已與一家全球醫療保健公司簽訂了爲期多年的商業供應合同，爲其在美國的設施提供DefenCath（牛磺利定和肝素）。
The company, which provides healthcare services to more than 2,000 clinics in the United States, expects to initially target the utilization of DefenCath in up to 4,000 patients nationally, that would be prioritized based upon medical need. CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare & Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the fourth quarter.
該公司爲美國2,000多家診所提供醫療服務，預計最初的目標是在全國多達4,000名患者中使用DefenCath，這將根據醫療需求進行優先排序。CorMedix於2023年11月15日根據抗菌和抗真菌藥物有限種群途徑（LPAD）獲得了DefenCath的保密協議批准，並於2024年4月15日開始在住院環境中將該產品商業化。醫療保險和醫療補助服務中心（CMS）對Defencath的門診報銷於7月1日生效，CorMedix隨後於7月開始發貨。CorMediX預計，根據該協議，Defencath的出貨將於第四季度開始。